scholarly journals Antibody Titers of Dairy Heifers following Vaccination with a Staphylococcal Toxoid

1969 ◽  
Vol 49 (1) ◽  
pp. 88-98
Author(s):  
José D. Rivera Anaya ◽  
Carlos M. Berrocal ◽  
G. Rosado Carbó
Keyword(s):  
Booster Dose ◽  
Milk Whey ◽  
Dairy Heifers ◽  
The Third ◽  
Serum Titer ◽  
Steep Decrease ◽  
Antibody Titers ◽  
General Average ◽  
Level 1 ◽  
Observation Period

Five milliliters of Slanetz No. 7 Staphylococcal Toxoid were injected intramuscularly into 43 pregnant heifers in 3 herds; a booster dose was given 1 month later. The antibody level in both the blood sera and the milk wheys of these heifers was determined through a 13-month period. The average blood-serum titer reached a 1:50 level 1 month after vaccination, and remained around that level until the fifth postvaccinal month. Thereafter, a continuous and rapid decrease in titer was observed until the 11th postvaccinal month. An increase in titer was observed after the annual booster dose was given. Although the staphylococcal antibody titers in milk wheys from two herds showed a peak in the third month, the levels went steeply down at the 5th-month observation. The general average trend was a steady and steep decrease in milk-whey antibody titer through the 11-month postvaccinal observation period, with a very feeble response after the annual booster dose.

COMBINED IMMUNIZATION AGAINST DIPHTHERIA, TETANUS AND PERTUSSIS IN NEWBORN INFANTS

PEDIATRICS ◽  
1949 ◽  
Vol 3 (2) ◽  
pp. 181-194
Author(s):  
PAUL A. DI SANT'AGNESE
Keyword(s):  
Booster Dose ◽  
Newborn Infants ◽  
Active Immunization ◽  
Striking Difference ◽  
Tetanus Antitoxin ◽  
The Third ◽  
Number Of Patients ◽  
Diphtheria Antitoxin ◽  
Antibody Titers ◽  
One Year

Additional serologic studies are presented of a group of newborn infants whose antibody production following combined prophylactic inoculation against tetanus, diphtheria and pertussis was reported in a previous paper. Duration of Antibody Titers: In the 10 months following the last injection of triple combined antigen a steady decline in diphtheria antitoxin titers was observed which was more marked in patients who had achieved high antibody levels. A similar decrease was found in the percentage of infants with high titers of tetanus antitoxin, but there were no cases whose tetanus antitoxin level dropped to less than the "protective" titer (0.1 unit/cc.). Progressive decrease in diphtheria and tetanus antitoxin titers with passage of time is in agreement with findings of others. After the third and last immunizing injection, a rapid initial decrease was noted in the number of patients with "protective" pertussis agglutinin titers (1:400 or higher); then a levelling off took place and no further change was noted in the next six months. On the other hand, a steady decline was found in the percentage of infants with "high" agglutinin levels (1:3200). To our knowledge this has not been observed before. The young age of our patients at the time of the basic injections may have been responsible for the findings. Antibody Titers After Booster Dose: One group of infants was reinjected at the age of six months (four months after the third and last immunizing injection), another group at one year of age (10 months after the last injection). All booster doses consisted of 0.5 cc. of the same triple combined antigen used in basic immunization. After booster a marked increase was noted in diphtheria antitoxin titers to a level higher than that observed following the basic immunizing injections. Tetanus antitoxin response was considered to have been equally good, although more difficult to evaluate because of the high antitoxin levels present before reinjection. In the case of pertussis agglutinins, it appeared as if there were a "ceiling" of about 60% of infants who could, even after reinjection, develop a "protective" agglutinin titer (1:400 or higher). A striking difference was observed in both pertussis agglutinin levels and diphtheria antitoxin titers achieved by infants reinjected at six months and one year of age. This was thought to be due to immaturity of the immune mechanisms in the younger age group. An added factor in the case of diphtheria antitoxin in some patients may have been the persistence of passive antibodies acquired transplacentally. Antibody titers also were determined six months after booster dose in the infants who had been reinjected at the age of six months. A marked decrease was observed in the percentage of patients with "protective" pertussis agglutinin titers and "high" (1.0 unit/cc.) diphtheria antitoxin levels. No reduction was noted in tetanus antitoxin titers. Effects of Passive immunity to Diphtheria on Active immunization with Diphtheria Toxoid: With only one exception, all infants tested after a booster dose had been administered between 6 and 12 months of age had "protective" diphtheria antitoxin titers (0.03 units/cc. or more). Active immunization against diphtheria was therefore considered to have been achieved in all cases (with one exception) despite the passively transmitted antitoxin present at birth in over half the cases. While passive diphtheria antitoxin present at birth did not prevent "sensitization" of the antibody-forming tissues to the diphtheria antigen, it did decrease significantly the amounts of antitoxin actively produced in response to basic inoculation. Reasons for the success of active diphtheria immunization in this series are discussed. Arguments against active immunization of mothers in pregnancy for protection of their offspring are considered.

scholarly journals Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers

2021 ◽  
Author(s):  
Maria Elena Romero-Ibarguengoitia ◽  
Diego Rivera-Salinas ◽  
Yodira Guadalupe Hernandez-Ruiz ◽  
Ana Gabriela Armendariz-Vazquez ◽  
Arnulfo Gonzalez-Cantu ◽  
...  
Keyword(s):  
Side Effects ◽  
Healthcare Workers ◽  
Booster Dose ◽  
Common Side Effect ◽  
Igg Antibody ◽  
Humoral Immune ◽  
The Third ◽  
Antibody Titers ◽  
Original Scheme ◽  
Prospective Longitudinal

Background: Vaccination is our main strategy to control SARS-CoV-2 infection. Given a decrease in the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months following the second BNT162b2 dose, healthcare workers got a third booster dose after six months of completing the original scheme. This study aimed to analyze quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and safety of the third dose. Material and methods: A prospective longitudinal cohort study included healthcare workers who received a third booster dose after six months of the complete BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the complete scheme, 1-7 days following the third dose, and 21-28 days after the boost. Results: The cohort comprised 168 non-immunocompromised participants of 41(10) years old, 67% being women. The third dose was associated with increasing the quantitative antibody titers, regardless of previous SARS-CoV-2 history. In negative SARS-CoV-2 history, the median (IQR) antibody titers increased from 379 (645.4) to 2960 (2010), while in positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080). The third dose had less number of total side effects compared to the other two shots. The most common side effect after the third BNT162b2 shot was pain at the injection site (n=82, 84.5%), followed by tiredness (n=45, 46.4%), with a mild severity (n=36, 37.1%). Tiredness, myalgias, arthralgias, fever, and adenopathy were proportionally higher following the third dose than the two-dose regimen (p<0.05). Conclusion: The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated with no severe side effects after the additional BNT162b2 dose.

MULTIPLE ANTIGEN IMMUNIZATION OF INFANTS AGAINST POLIOMYELITIS, DIPHTHERIA, PERTUSSIS, AND TETANUS

PEDIATRICS ◽  
1962 ◽  
Vol 30 (5) ◽  
pp. 720-736
Author(s):  
Clarence D. Barrett ◽  
I. William McLean ◽  
Joseph G. Molner ◽  
Eugene A. Timm ◽  
Charles F. Weiss
Keyword(s):  
Booster Dose ◽  
Active Immunization ◽  
Maternal Antibody ◽  
Control Group ◽  
Tetanus Antitoxin ◽  
The Third ◽  
Multiple Antigen ◽  
Primary Series ◽  
Initial Injection ◽  
Pertussis Antigen

This study was designed to determine the earliest age in infancy at which immunization against poliomyelitis, diphtheria, tetanus, and pertussis can be started using a multiple antigen containing component antigens against all four diseases. Subjects ranged in age from 1 day old through 6 months old at time of initial injection. All were given a series of four injections of 0.5 ml of DPT-polio antigen 4 weeks apart followed by a fifth dose (0.5 ml) of the same material 6 months later. A control group received 0.5 ml of a DPT antigen at monthly intervals for their first four doses, but were given a DPT-polio injection (0.5 ml) for their fifth dose. Although it is evident that there is a progressive response in relation to age of the infant at time of initial inoculation, in respect to poliomyelitis and pertussis immunization, it was apparent that the capacity of the 3-month-old infant to respond to active immunization closely approximates that of the 6-month-old. Ninety per cent showed definite evidence of an immune response to all three poliovirus types despite extremely high levels of preprimary maternal antibody in the majority of 3-month-old infants under study. Pertussis antibody response, as measured by agglutinin titers, was as good in the 3-month-old as in the 6-month-old infants. The response in the 2-month-old infants was relatively poor at the postprimary stage but was equivalent to that of the older infants at the postbooster interval. There was no indication that response to pertussis immunization was impaired by the inclusion of pertussis antigen in the quadrivalent antigen under study. Diphtheria and tetanus antitoxin titers were excellent regardless of age at initial inoculation. The results indicate that four doses of DPT-polio combined antigen given at monthly intervals will overcome the interference of high levels of maternal antibody in respect to poliomyelitis immunization and that the primary series of injections may be started as early as the third month of life. It is important, however, that this primary series of inoculations be followed by a booster dose of the same antigen preparation in about 6 months in order to reinforce the basic immunity.

THE PASSIVE TRANSFER OF ANTIBODIES TO ESCHERICHIA COLI 0111:B4 FROM MOTHER TO OFFSPRING

PEDIATRICS ◽  
1961 ◽  
Vol 27 (2) ◽  
pp. 308-313
Author(s):  
Sidney Sussman
Keyword(s):  
Escherichia Coli ◽  
Antibody Titer ◽  
Passive Transfer ◽  
The Third ◽  
Coli Antibody ◽  
Antibody Titers

Esch. coli antibody titers in 27 mothers and their respective offspring were studied by the trypsinated and nontrypsinated hemagglutination technic. All of the maternal sera and colostra contained Esch. coli 0111-B4 antibody. In 19 cases the antibody titer in the specimens of colostrum on the first day was higher than that of the corresponding sera. The antibody titer in the colstrum fell rapidly during the next 3 to 4 days. Five cord sera had a low antibody titer to Esch. coli 0111:B4 when tested by the trypsinated hemagglutination method. By contrast, only two cord sera were positive for Esch. coli 0111:B4 antibody when tested by the untrypsinated hemagglutination technic. With the trypsinated method, two infants showed a 2-tube rise and one infant had a 1-tube rise in titer at the end of the third colostrum day; one infant demonstrated a 1-tube rise in titer when tested by the untrypsinated hemagglutination technic. In general, there was a 1-to-3-tube difference between the trypsinated and untrypsinated hemagglutination procedures.

ADENOVIRUS COMPLEMENT-FIXING ANTIBODY TITERS FROM BIRTH THROUGH THE FIRST YEAR OF LIFE

PEDIATRICS ◽  
1963 ◽  
Vol 32 (4) ◽  
pp. 497-500
Author(s):  
Rosa Lee Nemir ◽  
Donna O'Hare ◽  
Stanley Goldstein ◽  
Charles B. Hilton
Keyword(s):  
Cytopathic Effect ◽  
Gradual Increase ◽  
Newborn Infants ◽  
First Year ◽  
Placental Barrier ◽  
Culture Studies ◽  
Antibody Titers ◽  
Level 1 ◽  
One Year ◽  
First Year Of Life

Complement fixing antibody titers to the adenoviruses were determined in 251 newborn infants, using cord blood. Approximately 95% of these were found to have CF titers of 1:16 or over, the majority (75%) were 1:32 or more. Material from the pharyngeal and rectal swabs of these infants on tissue culture studies (542) on HeLa and amnion cells showed no cytopathic effect in oven 96% of these infants. A longitudinal study of 114 of these infants was made at 3 months intervals; 67 have been observed for one year. At 3 months, only 12% still showed CF antibody titers, and these were chiefly at a low level, 1:16. At the subsequent 3-month interval observations, a gradual rise in CF antibodies were found. At one year of age, approximately 37% had titers of 1:32 on over. The findings of this report support the statement that CF antibodies to adenovirus pass the placental barrier. There is a gradual increase in the percentage of infants with positive CF antibodies after 3 months.

scholarly journals Hepatitis B antibody titers in Indonesian adolescents who received the primary hepatitis B vaccine during infancy

2013 ◽  
Vol 53 (3) ◽  
pp. 160
Author(s):  
Hartono Gunardi ◽  
Adra Firmansyah ◽  
Sri Rezeki S Harun ◽  
Sudigdo Sastroasmoro
Keyword(s):  
Hepatitis B ◽  
Booster Dose ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Blood Tests ◽  
Vaccination History ◽  
Antibody Titers ◽  
Hb Vaccine ◽  
Over Time

Backgi-ound Hepatitis B (HB) has been classified as moderate-tohighlyendemic in Indonesia. HB vaccination, the most effectivemethod to prevent HB viral transmission, induces protectiveantibodies against HB surface antigen (anti-HBs). However, theseantibodies decline in titer over time. Studies on the duration ofprotection and the prevalence of n on-responders in Indonesianadolescents have been limited.Objectives To determine anti-HBs titers in 15-17-year oldIndonesian adolescents given primary HB vaccine during infancyand the prevalence of non-responders after a HB vaccine boosterdosage.Methods This cross-sectional study was performed from Februaryto September 2008 on adolescents aged 15-17 years in threesenior high schools in Jakarta who received complete primary HBvaccines during infancy, based on parents' recall. Investigationsincluded HB vaccination history, anthropometric measurements,and blood tests for anti-HBs before and 4-6 weeks after a boosterdose ofHB vaccine.Results Of 94 subjects, 35 had protective anti-HBs and 59 hadundetectable anti-HBs. A booster dose was administered to 5 8 of then on-protected subjects, of which 33 showed anamnestic responses.However, 25 subjects failed to generate protective anti-HBs. Takinginto consideration the adolescents with protective anti-HBs beforeand after the booster dose, serologic protection was demonstratedin 73%. Non-responder prevalence was 27%. The high prevalenceof non-responders may indicate bias of parents' recall.Conclusion Protective anti-HBs is detected in less than half ofIndonesian adolescents given primary HB vaccine during infancy.Following booster dosage, anamnestic responses are n oted in onethirdof subjects. The prevalence of non-responders is 27%, butconfirmation with further study is needed.

Fibrinogen, Platelet and Red Cell Kinetics in Mice Bearing an Experimental Tumor

1975 ◽  
Author(s):  
A. Poggi ◽  
N. Polentarutti ◽  
M. B. Donati ◽  
G. de Gaetano ◽  
S. Garattini
Keyword(s):  
Cell Kinetics ◽  
Fibrinogen Level ◽  
Low Grade ◽  
Red Cell ◽  
Experimental Tumor ◽  
Tumor Implantation ◽  
The Third ◽  
Red Cell Survival ◽  
Observation Period

In view of the possible role of platelets and coagulation mechanisms in the growth and dissemination of solid tumors, a number of haematological parameters have been followed during development of an experimental syngeneic tumor in mice (Lewis Lung Carcinoma, 3LL). This tumor, when transplanted intramuscularly in C57,B1/6 mice, grows locally and gives spontaneous metastases to the lungs. The transplanted animals survive for about 4 weeks. Metastases are visible since the third week. A slight but constant increase in plasma fibrinogen level and a marked thrombocytopenia were observed starting during the second week after tumor implantation. No other significant changes in coagulation and fibrinolysis parameters were found. Moreover, the animals developed a marked haemolytic anaemia, possibly microangiopathic in origin. 125I-fibrinogen survival was decreased of about 20% during the second week after tumor implantation and was not further reduced later on. Fibrinogen turnover was accelerated since the second week and was further increased thereafter, being more than doubled at the end of the third week. Labelled fibrinogen accumulated in the primary tumor and in the lungs; its rats of disappearance from the tumor was much slower than from lungs or blood. These data suggest the occurrence of a low-grade, localized fibrinogen consumption (intravascular coagulation ?). 51Cr-platelet survival was not modified throughout the observation period, whereas platelet turnover was markedly reduced since the end of the second week, suggesting a defective platelet production. 51Cr-red cell survival was drastically reduced to about 30% of controls starting from the second week, whereas labelled red cell turnover was almost doubled. The pathogenetic relevance of the observed modifications in the processes of grwoth and dissemination of 3 LL remains to be established.(Supported by Grant NIH-PHRB-IRO1 CA 12764–01.

scholarly journals Durability of Response to a Third BNT162b2 Vaccine in Adults ≥60 Years

2021 ◽  
Author(s):  
Noa Eliakim Raz ◽  
Amos Stemmer ◽  
Yaara Leibovici-Weissman ◽  
Asaf Ness ◽  
Muhammad Awwad ◽  
...  
Keyword(s):  
Adverse Events ◽  
Neutralizing Antibodies ◽  
Multivariable Analysis ◽  
Vaccine Dose ◽  
Neutralizing Antibody ◽  
Clinical Frailty Scale ◽  
Younger Adults ◽  
The Third ◽  
Antibody Titers ◽  
Level 2

BACKGROUND Age and frailty are strong predictors of COVID-19 mortality. After the second BNT162b2 dose, immunity wanes faster in older (≥65 years) versus younger adults. The durability of response after the third vaccine is unclear. METHODS This prospective cohort study included healthcare workers/family members ≥60 years who received a third BNT162b2 dose. Blood samples were drawn immediately before (T0), 10-19 (T1), and 74-103 (T2) days after the third dose. Antispike IgG titers were determined using a commercial assay, seropositivity was defined as ≥50 AU/mL. Neutralizing antibody titers were determined at T2. Adverse events, COVID-19 infections, and clinical frailty scale (CFS) levels were documented. RESULTS The analysis included 97 participants (median age, 70 years [IQR, 66-74], 61% women, 58% CFS level 2). IgG titers, which increased significantly from T0 to T1 (medians, 440 AU/mL [IQR, 294-923] and 25,429 [14,203-36,114] AU/mL, respectively; P<0.001), decreased significantly by T2, but all remained seropositive (median, 8,306 AU/mL [IQR, 4595-14,701], P<0.001 vs T1). In a multivariable analysis, only time from the first vaccine was significantly associated with lower IgG levels at T2 (P=0.004). At T2, 60 patients were evaluated for neutralizing antibodies; all were seropositive (median, 1,294 antibody titer [IQR, 848-2,072]). Neutralizing antibody and antispike IgG levels were correlated (R=0.6, P<0.001). No major adverse events or COVID-19 infections were reported. CONCLUSIONS Antispike IgG and neutralizing antibodies levels remain adequate 3 months after the third BNT162b2 vaccine in healthy adults ≥60 years, although the decline in IgG is concerning. A third vaccine dose in this population should be top priority.

scholarly journals Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose

2021 ◽  
Author(s):  
Merav Mofaz ◽  
Matan Yechezkel ◽  
Grace Guan ◽  
Margaret L. Brandeau ◽  
Tal Patalon ◽  
...  
Keyword(s):  
Heart Rate ◽  
Heart Rate Variability ◽  
Booster Dose ◽  
Vaccination Campaign ◽  
Vaccine Dose ◽  
P Value ◽  
Booster Vaccine ◽  
The Third ◽  
Systemic Reactions ◽  
Physiological Reactions

AbstractBackgroundThe rapid rise in hospitalizations associated with the Delta-driven COVID-19 resurgence, and the imminent risk of hospital overcrowding, led the Israeli government to initialize a national third (booster) COVID-19 vaccination campaign in early August 2021, offering the BNT162b2 mRNA vaccine to individuals who received their second dose over five months ago. However, the safety of the third (booster) dose has not been fully established yet.ObjectiveEvaluate the short-term, self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.DesignA prospective observational study, in which participants are equipped with a smartwatch and fill in a daily questionnaire via a dedicated mobile application for a period of 21 days, starting seven days before the vaccination.SettingAn Israel-wide third (booster) vaccination campaign.ParticipantsA group of 1,609 (18+ years of age) recipients of at least one dose of the BNT162b2 vaccine between December 20, 2020, and September 15, 2021, out of a larger cohort of 2,912 prospective study participants. 1,344 of the participants were recipients of the third vaccine dose.MeasurementsDaily self-reported questionnaires regarding local and systemic reactions, mood level, stress level, sport duration, and sleep quality. Heart rate, heart rate variability and blood oxygen saturation level were continuously measured by Garmin Vivosmart 4 smartwatches.ResultsThe extent of systemic reactions reported following the third (booster) dose administration is similar to that reported following the second dose (p-value=0.305) and considerably greater than that reported following the first dose (p-value<0.001). Our analyses of self-reported well-being indicators as well as the objective heart rate and heart rate variability measures recorded by the smartwatches further support this finding. Focusing on the third dose, reactions were more apparent in younger participants (p-value<0.01), in women (p-value<0.001), and in participants with no underlying medical conditions (p-value<0.001). Nevertheless, reported reactions and changes in physiological measures returned to their baseline levels within three days from inoculation with the third dose.LimitationsParticipants may not adequately represent the vaccinated population in Israel and elsewhere.ConclusionOur work further supports the safety of a third COVID-19 BNT162b2 mRNA (booster) vaccine dose from both a subjective and an objective perspective, particularly in individuals 65+ years of age and those with underlying medical conditions.Primary funding sourceEuropean Research Council (ERC) project #949850

scholarly journals SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population

Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 18
Author(s):  
Marwa O. Elgendy ◽  
Ahmed O. El-Gendy ◽  
Abdulaziz Ibrahim Alzarea ◽  
Sarah Mahmoud ◽  
Saad S. Alqahtani ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Laboratory Tests ◽  
Dose Interval ◽  
Vaccine Safety ◽  
Spike Protein ◽  
Post Vaccination ◽  
The Third ◽  
Antibody Titers ◽  
Administration Methods ◽  
Structured Questionnaire

Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divided into three parts, the first and second parts were to detect participants’ post-first and second dose symptoms and practices, and the third for the results of IgG anti spike protein antibodies test and laboratory tests. Pain, redness, swelling at the injection site, headache, fatigue, and lethargy were the most common post-vaccine symptoms for both first and second doses. Most of the participants felt mild or no symptoms after vaccination. The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Forty-nine percent of the participants resulted in positive antibodies tests on day 18 post-vaccination. The average antibody level for vaccinated participants with past SARS-CoV-2 infection was much higher than that for non-past infected participants. These vaccines’ administration methods need to be reevaluated by changing the dose, dose interval, adding a third dose, or mixing it with other vaccines with different techniques to improve their protection rates. Further studies are required to validate this finding.

Sign in / Sign up

Export Citation Format

Share Document